Rep. Lisa C. McClain Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Posted by Teresa Graham on Nov 26th, 2025

Representative Lisa C. McClain (R-Michigan) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

AbbVie Trading Down 1.5%

Shares of AbbVie stock traded down $3.58 during trading hours on Wednesday, hitting $228.22. The company’s stock had a trading volume of 889,610 shares, compared to its average volume of 6,390,578. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a market capitalization of $403.36 billion, a PE ratio of 108.70, a P/E/G ratio of 1.42 and a beta of 0.50. The business has a fifty day moving average of $227.36 and a 200 day moving average of $206.12. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the company earned $3.00 EPS. The firm’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research note on Tuesday, November 4th. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. HSBC set a $225.00 price target on shares of AbbVie in a research report on Thursday, October 2nd. Finally, Bank of America boosted their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $241.85.

View Our Latest Stock Report on AbbVie

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ellenbecker Investment Group lifted its holdings in AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA lifted its stake in AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC boosted its holdings in shares of AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock valued at $4,066,000 after acquiring an additional 45 shares during the period. Centennial Wealth Advisory LLC grew its position in shares of AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after acquiring an additional 45 shares during the last quarter. Finally, Willner & Heller LLC grew its position in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after acquiring an additional 46 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About AbbVie

(Get Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.